Benzinga.com4d
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...
Yahoo Finance5d
Keytruda keys in on survival: Promising results in high-risk early-stage TNBC from KEYNOTE-522
At the European Society for Medical Oncology Congress on September 13–17, promising results from the Phase III KEYNOTE-522 study involving MSD's neoadjuvant Keytruda (pembrolizumab) plus ...
Nasdaq3d
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...
Yahoo Finance4d
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...
Cure Today5d
FDA Approves Keytruda Plus Chemo for Pleural Mesothelioma Subset
Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...
Cure Today7d
Presurgical Keytruda-Chemo Combo With Postsurgical Keytruda May Improve Survival in Early TNBC
Patients with early triple-negative breast cancer had improved survival outcomes after receiving presurgical Keytruda plus chemotherapy and postsurgical Keytruda. Patients with early-stage ...
FiercePharma7d
ESMO: With survival win, Merck's Keytruda redeems itself in early triple-negative breast cancer
In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...
Business Insider4d
Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults
(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination with ...
MarketWatch4d
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
Seeking Alpha8d
Merck Keytruda cuts mortality risk by 33% in late-stage trial for cervical cancer
Merck (NYSE:MRK) announced Saturday that its ant-PD-1 therapy Keytruda (pembrolizumab) reached the main goal in a Phase 3 trial with chemoradiotherapy in patients with cervical cancer, cutting ...
Seeking Alpha4d
Merck’s Keytruda label expanded in the U.S. for mesothelioma
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination ...